INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1801-01000	Appln. No.	Not Yet Assigned	10/631,867
Applicant	Heiner GLOMBIK et al.			
Filing Date	Herewith	Group:	Not Yet Assigned	

		U.S. PATEN	T DOCUMENTS			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
FTP	6,380,230	4/2002	Brodin et al.	1	75	
1	6,342,512	1/2002	Kirsch et al.	17		
	6,245,744	6/2001	Frick et al.			
	6,221,897	4/2001	Frick et al.	17.00		
	6,221,633	4/2001	Ertl et al.			
	5,814,647	9/1998	Urban et al.			
$\sqrt{}$	5,190,923	3/1993	Vincent et al.			
1TP	3,174,901	3/1965	Sterne	T.Y_	_Y_	
· ·		FOREIGN PAT	ENT DOCUMENT	S		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
ITP	98/08871	3/1998	PCT			
<u></u>	97/26265	7/1997	PCT	11		·
	99/03861	1/1999	PCT			
	97/41097	11/1997	PCT			
	01/91752	12/2001	PCT			
	00/63208	10/2000	PCT			
	WO 00/64876	11/2000	PCT			
	00/66585	11/2000	PCT			
	01/83451	11/2001	PCT			Abstract
	99/15525	4/1999	PCT			Abstract
	00/71549	11/2000	PCT			
	01/09111	2/2001	PCT			
	01/85695	11/2001	PCT			
	0 462 884	12/1991	EUROPEAN			
	00/40569	7/2000	PCT			
1	00/78312	12/2000	PCT			
7TP	97/28149	8/1997	PCT	1	.V	

Page 1 of 4

INFORMATION DISCLOSURE-CITATION

Atty. Docket No.	02481.1801-01000	Appln. No.	Not Yet Assigned	10/631,867
Applicant	Heiner GLOMBIK et al.			
Filing Date	Herewith	Group:	Not Yet Assigned	

		U.S. PATEN	T DOCUMENTS			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
778	00/64888	11/00	PCT			
FTP	00/64876	11/00	PCT			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
1 m	Beck et al., "The Ontogeny Of Peroxisome-Proliferator-Activated Receptor Gene Expression In The Mouse And Rat," <u>Proc. R. Soc. Lond. B</u> , 247:83-87 (1992).
1	OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas," Chem. Pharm. Bull., 42(1), 57-61 (1994).
	LEE et al., "Leptin Agonists as a Potential Approach to the Treatment of Obesity," Drugs of the Future, 26(9), 873-881 (2001).
	SALVADOR et al., "Perspectives in the Therapeutic Use of Leptin," Expert Opin. Pharmacother., 2(10), 1615-1622 (2001).
	ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia," Advances in Therapy, 18(5), 230-236 (2001).
	MOTOJIMA, "Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions," Cell Structure and Function, 18, 267-277 (1993).
	TYLE, "Iontophoretic Devices for Drug Delivery," Pharmaceutical Research, 3(6), 318-326 (1986).
	HORIKOSHI et al., "TroglitazoneA Novel Antidiabetic Drug for Treating Insulin Resistance," DDT, 3(2), 79-88 (1998).
	DEMETRI et al., "Induction of Solid Tumor Differentiation by the Peroxisome Proliferator-Activated Receptor-γ Ligand Troglitazone in Patients with Liposarcoma," Proc. Natl. Acad. Sci. USA, 96, 3951-3956 (1999).
	ELSTNER et al., "Ligands for Peroxisome Prolierator-Activated Receptor γ and Retinoic Acid Receptor Inhibit Growth and Induce Apoptosis of Human Breast Cancer Cells <i>in vitro</i> and in BNX Mice," Proc. Natl. Acad. Sci. USA, 95, 8806-8811 (1998).
	SARRAF et al., "Differentiation and Reversal of Malignant Changes in Colon Cancer through PPARy," Nature Medicine, 4(9), 1046-1052 (1998).
	DUNAIF et al., "The Insulin-Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome," J. Clin. Endocrinol. Metab., 81(9), 3299-3306 (1996).
	LÖHRKE et al., "Detection and Functional Characterisation of the Transcription Factor Peroxisome Proliferator-Activated Receptor y in Lutein Cells," Journal of Endocrinology, 159, 429-439 (1998).
+TP	POYNTER et al., "Peroxisome Proliferator-Activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κβ Signaling, and Reduces Inflammatory Cytokine Production in Aging," J. Biol. Chem., 273(49), 32833-32841 (1998).

INFORMATION DISCLOSURE, CITATION

Atty. Docket No.	02481.1801-01000	Appln. No.	Not Yet Assigned	10/631,867
Applicant	Heiner GLOMBIK et al.			
Filing Date	Herewith	Group:	Not Yet Assigned	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
1TP	PINEDA-TORRA et al., "Peroxisome Proliferator-Activated Receptor Alpha in Metabolic Disease, Inflammation, Atherosclerosis and Aging," Curr. Opinion in Lipidology, 10, 151-159 (1999).
	COLVILLE-NASH et al., "Inhibition of Inducible Nitric Oxide Synthase by Peroxisome Proliferator-Activated Receptor Agonists: Correlation with Induction of Heme Oxygenase 1," Journal of Immunology, 161, 978-984 (1998).
	STAELS et al., "Activation of Human Aortic Smooth-Muscle Cells is Inhibited by PPARa but not by PPARy Activators," Nature, 393, 790-793 (1998).
	GREEN, "Receptor-Mediated Mechanisms of Peroxisome Proliferators," Biochemical Pharmacology, 43(3), 393-401 (1992).
	GÖTTLICHER et al., "Fatty acids Activate a Chimera of the Clofibric Acid-Activated Receptor and the Glucocorticoid Receptor," Proc. Natl. Acad. Sci. USA, 89, 4653-4657 (1992).
	SCHOONJANS, "Peroxisome Proliferator-Activated Receptors, Orphans with Ligands and Functions," Current Opinion in Lipidology, 8, 159-166 (1997).
	SCHMIDT et al., "Identification of a New Member of the Steroid Hormone Receptor Superfamily that is Activated by a Peroxisome Proliferator and Fatty Acids," Molecular Endocrinology, 6, 1634-1641 (1992).
	AMRI et al., "Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes," J. Biol. Chem., 270(5), 2367-2371 (1995).
	FRICK et al., "Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men with Low Levels of HDL Cholesterol," Circulation, 96, 2137-2143 (1997).
	De FAIRE et al., "Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic Trials," Cardiovasc. Drugs Ther., 11, 257-263 (1997).
	LEHMANN et al., "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)," J. Biol. Chem., 270(22), 12953-12956 (1995).
	ELBRECHT et al., "Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2," BBRC, 224, 431-437 (1996).
	FORMAN et al., "15-Deoxy- $\Delta^{12, 14}$ -Prostaglandin J ₂ Is a Ligand for the Adipocyte Determination Factor PPARy," 83, 803-812 (1995).
	KLIEWER et al., "A Prostaglandin J_2 Metabolite Binds Peroxisome Proliferator-Activated Receptor γ and Promotes Adipocyte Differentiation," Cell, 83, 813-819 (1995).
	STAELS et al., "Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones," Curr. Pharm. Des., 3(1), 1-14 (1997).
	FRUCHART et al., "PPARS, Metabolic Disease and Atherosclerosis," Pharmacol. Research, 44(5), 345-352 (2001).
FTP	KERSTEN et al., "Roles of PPARs in Health and Disease," Nature, 405, 421-424 (2000).

INFORMATION DISCLOSURE/CITATION

Atty. Docket No.	02481.1801-01000	Appln. No.	Not Yet Assigned	10/631,867
Applicant	Heiner GLOMBIK et al.	-		
Filing Date	Herewith	Group:	Not Yet Assigned	

Filing Date	Herewith	Group: Not Yet Assigned		
	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pages, Etc.)		
FTP	PINEDA-TORRA et al., "Peroxisom to Clinical Practice," Curr. Opin. Lip	e Proliferator-Activated Receptors: From Transcriptional Control idol., 12, 245-254 (2001).		
J M		ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice," Hormone & Metabolic Research, 33, 554-558 (2001).		
778		Vidal-Puig et al., "Regulation of PPAR γ Gene Expression By Nutrition And Obesity In Rodents," J. Clin. Invest., 97(11):2553-2561 (1996).		
Examiner A	Date Considered 5/5/04			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
Form PTO 1449	Patent ar	nd Trademark Office - U.S. Department of Commerce		

400201-1